GMFR in NT50 at 14 Days and 6 Months After Second Vaccination;NT50 GMT at 14 Days and 6 Months After Second Vaccination;Percentage of Participants With AE of Special Interest by Severity and Relatedness Throughout the Entire Study Period;Percentage of Participants With Local and Systemic Solicited AEs by Severity During the First 7 Days After Each Vaccination.;Percentage of Participants With SAEs Severity and Relatedness Throughout the Entire Study Period;Percentage of Participants With Unsolicited AEs by Severity and Relatedness During the First 28 Days After Each Vaccination;Percentage of Subjects With Seroresponse in NT50 at 14 Days and 6 Months After Second Vaccination

GMFR in NT50 at 14 Days and 6 Months After Second Vaccination;NT50 GMT at 14 Days and 6 Months After Second Vaccination;Percentage of Participants With AE of Special Interest by Severity and Relatedness Throughout the Entire Study Period;Percentage of Participants With Local and Systemic Solicited AEs by Severity During the First 7 Days After Each Vaccination.;Percentage of Participants With SAEs Severity and Relatedness Throughout the Entire Study Period;Percentage of Participants With Unsolicited AEs by Severity and Relatedness During the First 28 Days After Each Vaccination;Percentage of Subjects With Seroresponse in NT50 at 14 Days and 6 Months After Second Vaccination

AE of Special interest (AESI);GMFR in NT50;NT50 GMT;SAE;Seroresponse in NT50;Solicited AE;Unsolicited AE

AE of Special interest (AESI);GMFR in NT50;NT50 GMT;SAE;Seroresponse in NT50;Solicited AE;Unsolicited AE